WO2001066117A1 - Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor - Google Patents
Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor Download PDFInfo
- Publication number
- WO2001066117A1 WO2001066117A1 PCT/GB2001/001047 GB0101047W WO0166117A1 WO 2001066117 A1 WO2001066117 A1 WO 2001066117A1 GB 0101047 W GB0101047 W GB 0101047W WO 0166117 A1 WO0166117 A1 WO 0166117A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analogue
- derivative
- use according
- metronidazole
- hydrogen pump
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 title claims abstract description 16
- 229960000282 metronidazole Drugs 0.000 title claims abstract description 15
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 10
- 208000017520 skin disease Diseases 0.000 title claims abstract description 10
- 229960003276 erythromycin Drugs 0.000 title claims abstract description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title claims description 10
- 230000002496 gastric effect Effects 0.000 title claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 title claims description 10
- 239000001257 hydrogen Substances 0.000 title claims description 10
- 239000003112 inhibitor Substances 0.000 title claims description 9
- 201000004700 rosacea Diseases 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 21
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960000381 omeprazole Drugs 0.000 claims abstract description 15
- 229960002626 clarithromycin Drugs 0.000 claims abstract description 8
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 241001303601 Rosacea Species 0.000 claims description 21
- 238000007911 parenteral administration Methods 0.000 claims description 6
- 238000011200 topical administration Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 206010000513 Acne pustular Diseases 0.000 claims description 2
- 208000009675 Perioral Dermatitis Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 16
- 239000000890 drug combination Substances 0.000 description 6
- 206010037888 Rash pustular Diseases 0.000 description 4
- 230000008029 eradication Effects 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 208000029561 pustule Diseases 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 206010043189 Telangiectasia Diseases 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 208000009056 telangiectasis Diseases 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241001128004 Demodex Species 0.000 description 1
- 241000193880 Demodex folliculorum Species 0.000 description 1
- 208000001384 Facial Dermatoses Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 201000010278 facial dermatosis Diseases 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Definitions
- the present invention relates to the treatment of skin 5 conditions such as rosacea and similar inflammatory dermatoses, and m particular to the treatment of certain kinds of rosacea, and also perioral papular and pustular acne, and other papulopustular dermatoses.
- Rosacea is a chronic inflammatory disease which affects the face. It is characterised by episodic flushing, erythema, and telangiectasia affecting the cheeks, chin, forehead, and nose. It may be further complicated by inflammatory swelling, papules and pustules.
- H. Pylori Gram-negative bacterium Helicobacter pylori
- rosacea and similar inflammatory skin dermatoses can be effectively treated by administering to a patient a treatment regime comprising I) erythromycm, clarithromycm or an analogue or derivative thereof, n) metronidazole or an analogue or derivative thereof, and m) a gastrointestinal hydrogen pump inhibitor, such as omeprazole or an analogue or derivative thereof.
- the three drugs may be formulated for simultaneous, separate or sequential use.
- the triple drug combination according to the present invention functions in achieving the desired results.
- One possibility is that there may be a causal relationship between the dermatoses to be treated and H. pylori , such that eradication of H. pylori may lead to resolution of these dermatoses.
- Another possibility is that as, certain instances, the presence of H. pylori has been found m pustules on the skin, the triple drug combination may act directly to eradicate that external form of H. pylori .
- triple drug combination works m another manner, such that any apparent relationship between its use m the present invention and H .pylori may simply be coincidental, such that further study will be necessary elucidate its precise mode of action Description of the Invention
- the preferred treatment regime comprises erythromycm or clarithromycm, metronidazole and omeprazole, and the most preferred treatment regime comprises clarithromycm, metronidazole and omeprazole.
- analogues or derivatives of any of these drugs may be used provided that their combined administration achieves the desired result.
- another similar-acting macrolide antibiotic to erythromycm or clarithromycm may be used, for instance azithromycm or dirithromyc .
- lanzoprazole or any other drug which acts to inhibits a gastrointestinal hydrogen pump may be used instead of omeprazole.
- the three drugs may be useful which have a similar or equivalent pharmacological mode of action to the drugs named above.
- Pharmaceutically- acceptable salt forms of the drugs may also be used.
- Treatment may be by administration of the three drugs by any suitable means. Conveniently, however, the three drugs will be administered by one or a combination of oral administration, topical application to a patient's skin, or parenteral administration, e.g. intravenous, intramuscular or subcutaneous administration. For instance, one or more of the three drugs may be formulated for administration by a different route to the other drug(s) . Typically, it is desirable to administer omeprazole or an analogue thereof orally, but the other drugs may be formulated for oral, topical or parenteral administration, or any combination thereof. For instance, it may be preferred to administer omeprazole orally and the other two drugs topically, optionally as a combined topical formulation.
- the triple drug combination may take the form of separate pills containing each of the separate drugs, for simultaneous, separate or sequential administration.
- the three drugs will be combined into a single dosage form, preferably a tablet, capsule or linctus, for patient convenience.
- the drugs are incorporated into a suitable pharmaceutically-acceptable carrier.
- suitable pharmaceutically-acceptable carrier Such formulations have not been disclosed in the prior art, and constitute further aspects of the claimed invention.
- the relative proportions of the three drugs necessary for effective treatment may vary depending on the route of administration, and the particular patient to be treated.
- a patient will receive 200 to 600 mg, preferably 300 to 500 mg of erythromycin, clarithromycin or an analogue thereof, 200 to 500 mg, preferably 300 to 500 mg, metronidazole, and 10 to 100 mg, preferably 20 to 60 mg, omeprazole, on a daily basis.
- a particularly preferred treatment regime comprises about 250 mg erythromycin, clarithromycin or an analogue thereof, about 400 mg metronidazole and about 20 mg omeprazole.
- Treatment periods vary from patient to patient, from one week to a number of years .
- a score of one is given if less than half the area involved is affected by that parameter, and a score of two if half or more of the area is affected.
- the scores for the different parameters in the different facial areas are added together to give a total score for the patient.
- Each patient was subjected to clinical photography, and then treated with an oral dosage of 20 mg omeprazole, 400 mg metronidazole, and 250 mg clarithromycin for one week.
- Disease severity scoring and clinical photography were repeated at the end of weeks 6, 12, 18, and 24, and fourteen patients were followed for a period of 52 weeks.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Use of i) erythromycin, clarithromycin or an analogue or derivative thereof; ii) metronidazole or an analogue or derivative thereof; and iii) omeprazole or an analogue or derivative thereof, for the manufacture of a medicament for the treatment of a condition selected from the group consisting of inflammatory dermatomes, and in particular papulopustular rosacea and similar inflammatory papulopustular dermatoses.
Description
TREATMENT OF INFLAMMATORY DERMATOSES COMPRISING ERYTHROMYCIN OR CLARYTHROMYCIN, METRONIDAZOLE AND A GASTROINTESTINAL HYDROGEN PUMP INHIBITOR
Field of the Invention
The present invention relates to the treatment of skin 5 conditions such as rosacea and similar inflammatory dermatoses, and m particular to the treatment of certain kinds of rosacea, and also perioral papular and pustular acne, and other papulopustular dermatoses. Background to the Invention
10 Rosacea is a chronic inflammatory disease which affects the face. It is characterised by episodic flushing, erythema, and telangiectasia affecting the cheeks, chin, forehead, and nose. It may be further complicated by inflammatory swelling, papules and pustules.
15 It is observed more frequently m women than m men, with an age of onset between 30 and 50, most commonly m those of Celtic or northern European descent.
Current treatments of rosacea include long-term the use of systemic or topical antibiotics, such as
20 tetracyclme, minocyclme, doxicyclme, erythromycm and metronidazole. However, such treatments are ineffective in achieving eradication of the condition, even for relatively short periods of time.
Many theories have been proposed to explain the
25 aetiology of rosacea, with a view to finding alternative treatments thereof. An association with gastrointestinal disease has been considered as long ago as 1920 when achlorhdria and hypochlorohydria were thought to be predisposing factors. However, attempts to confirm such an
30 association have been unsuccessful. Hypersensitivity to Demodex folli culorum, a mite which inhabits the facial pilosebaceous follicle, has also been postulated to be of relevance, and increased numbers of Demodex mites have been demonstrated m rosacea.
35 The association between rosacea and gastrointestinal disease has been revisited since the discovery that the Gram-negative bacterium Helicobacter pylori (H. Pylori ) is
the cause of gastritis and duodenal ulcer disease. Based on case-series studies of rosacea, several authors have reported higher than expected H. pylori seroprevalance and antibody titres, and have commented on improvement m the dermatological condition following H. pylori eradication therapy; see Rebora et al , Dermatology (1995) 89 : 1603-1604 , Kolibasora et al , Archives of Dermatology (1996) 132 : 1393 , and Utas et al , J.AM.Acad. Dermatology (1999) 40=433-435. Yet none of these studies employed proper controls for their results to be considered meaningful. Furthermore, a number of other studies have failed to confirm the alleged relationship between H . Pylori and rosacea; see Jones et al , Archives of Dermatology (1998) 134.: 511, and Bamford et al , Archives of Dermatology (1999) 135 : 659-663. The situation m this respect, therefore, remains conflicting and unclear, as does the cause of this common, yet poorly understood, facial dermatosis. Summary of the Invention
Surprisingly, and as a result of case-controlled studies, we have now found that rosacea and similar inflammatory skin dermatoses can be effectively treated by administering to a patient a treatment regime comprising I) erythromycm, clarithromycm or an analogue or derivative thereof, n) metronidazole or an analogue or derivative thereof, and m) a gastrointestinal hydrogen pump inhibitor, such as omeprazole or an analogue or derivative thereof. The three drugs may be formulated for simultaneous, separate or sequential use.
These studies have also lead us to believe that the different signs of rosacea expressed by patients may in fact have different causes, and may not be linked to one another. For some time, it has been believed that the different signs of rosacea are merely symptomatic of different, progressive, stages of the same general condition. Specifically, it has been suggested that the seemingly lesser signs of inflammatory rosacea (erythema and telangiectasis) progress to lesions and/or
papulopustular signs (pimples on the skin) . We believe that this may not be true, as patients have been observed to exhibit either inflammatory signs or papulopustular signs. Instead, the different signs may represent distinct types of rosacea.
While the triple drug combination described above is useful treating rosacea as a generality, we have discovered that it is particularly useful m the treatment of papulopustular rosacea, perioral dermatitis (peπoral rosacea), and perioral pustular or papular acne.
At present, it is not understood how the triple drug combination according to the present invention functions in achieving the desired results. One possibility is that there may be a causal relationship between the dermatoses to be treated and H. pylori , such that eradication of H. pylori may lead to resolution of these dermatoses. Another possibility is that as, certain instances, the presence of H. pylori has been found m pustules on the skin, the triple drug combination may act directly to eradicate that external form of H. pylori . Yet another possibility is that the triple drug combination works m another manner, such that any apparent relationship between its use m the present invention and H .pylori may simply be coincidental, such that further study will be necessary elucidate its precise mode of action Description of the Invention
The preferred treatment regime comprises erythromycm or clarithromycm, metronidazole and omeprazole, and the most preferred treatment regime comprises clarithromycm, metronidazole and omeprazole. As mentioned above, however analogues or derivatives of any of these drugs may be used provided that their combined administration achieves the desired result. For instance, another similar-acting macrolide antibiotic to erythromycm or clarithromycm may be used, for instance azithromycm or dirithromyc . Similarly, lanzoprazole or any other drug which acts to inhibits a gastrointestinal hydrogen pump, may be used
instead of omeprazole. Additionally, other drugs may be useful which have a similar or equivalent pharmacological mode of action to the drugs named above. Pharmaceutically- acceptable salt forms of the drugs may also be used. Treatment may be by administration of the three drugs by any suitable means. Conveniently, however, the three drugs will be administered by one or a combination of oral administration, topical application to a patient's skin, or parenteral administration, e.g. intravenous, intramuscular or subcutaneous administration. For instance, one or more of the three drugs may be formulated for administration by a different route to the other drug(s) . Typically, it is desirable to administer omeprazole or an analogue thereof orally, but the other drugs may be formulated for oral, topical or parenteral administration, or any combination thereof. For instance, it may be preferred to administer omeprazole orally and the other two drugs topically, optionally as a combined topical formulation.
If the triple drug combination is to be administered orally, it may take the form of separate pills containing each of the separate drugs, for simultaneous, separate or sequential administration. Preferably, however, the three drugs will be combined into a single dosage form, preferably a tablet, capsule or linctus, for patient convenience. In the case of topical or parenteral administration, the drugs are incorporated into a suitable pharmaceutically-acceptable carrier. Such formulations have not been disclosed in the prior art, and constitute further aspects of the claimed invention. The relative proportions of the three drugs necessary for effective treatment may vary depending on the route of administration, and the particular patient to be treated. Typically, however, a patient will receive 200 to 600 mg, preferably 300 to 500 mg of erythromycin, clarithromycin or an analogue thereof, 200 to 500 mg, preferably 300 to 500 mg, metronidazole, and 10 to 100 mg, preferably 20 to 60 mg, omeprazole, on a daily basis. A particularly preferred
treatment regime, however, comprises about 250 mg erythromycin, clarithromycin or an analogue thereof, about 400 mg metronidazole and about 20 mg omeprazole. Treatment periods vary from patient to patient, from one week to a number of years .
The results upon which the present invention are based are summarised in the following example. Example
42 patients with rosacea and evidence of infection with H. pylori were studied. At week 0, an initial assessment of the severity of each of the patient's skin disease was made, using the so-called "Coventry Scoring System"; see Br . J. Derm. (1995) 133, Suppl . 45, 34. This scoring system, developed in the Dermatology Department at Walsgrave Hospital, Coventry, UK, measures the severity of rosacea in five different facial areas and for six different parameters. The different facial areas are depicted in Figure 1, below. The different parameters are erythema, telangiectasia, papules, pustules, oedema and scaling. For each parameter in each area, a score of one is given if less than half the area involved is affected by that parameter, and a score of two if half or more of the area is affected. The scores for the different parameters in the different facial areas are added together to give a total score for the patient.
Each patient was subjected to clinical photography, and then treated with an oral dosage of 20 mg omeprazole, 400 mg metronidazole, and 250 mg clarithromycin for one week. Disease severity scoring and clinical photography were repeated at the end of weeks 6, 12, 18, and 24, and fourteen patients were followed for a period of 52 weeks.
At week 0 the mean severity score was 10 (range 3-24) .
Following treatment, at week 6 the mean score had fallen to
5.8 (range 2-12), falling further to 4.6 (range 2-8) at week 12. At weeks 18 and 24 the mean severity scores were 4.5 (range 2-12) and 5.6 (range 2-14) respectively. There was a significant difference between scores at week 0 and
weeks 6 and 12 (p<0.0001), and also between scores at week 0 and weeks 18, and 24 (p<0.001) . Five relapses were recorded, one at week 18 and four at week 24, with rosacea severity scores returning to values seen at week 0. The study demonstrates that the combined treatment of omeprazole, metronidazole and clarithromycin was effective in the treatment of symptoms associated with rosacea in general . It was noted in particular that the treatment significantly reduced papules and/or pustules on patients' faces.
While the study treated patients with evidence of infection with H. pylori , because a causal relationship between successful treatment of rosacea and eradication of H. pylori is yet to be confirmed, it is believed that the triple drug combination of the present invention may be useful in the treatment of patients who are not infected with H. pylori .
Claims
1 . Use of l) erythromycm, clarythromyc or an analogue or derivative thereof; li ) metronidazole; or an analogue or derivative thereof ; and in) a gastrointestinal hydrogen pump inhibitor, for the manufacture of a medicament for the treatment of a condition selected from the group consisting of inflammatory dermatoses.
2. Use according to claim 1, wherein the condition is rosacea .
3. Use according to claim 1, wherein the condition is an inflammatory papular or pustular dermatitis.
4. Use according to claim 3, wherein the condition is papulopustular rosacea.
5. Use according to claim 1, wherein the condition is perioral dermatitis.
6. Use according to claim 1, wherein the condition is perioral papular or pustular acne.
7. Use according to any preceding claim, wherein the gastrointestinal hydrogen pump inhibitor is omeprazole or an analogue or derivative thereof.
8. Use according to any preceding claim, wherein the medicament is for oral administration.
9. Use according to any of claims 1 to 8, wherein the medicament is for topical administration.
10. Use according to any of claims 1 to 8, wherein the medicament is for parenteral administration.
11. Use according to any of claims 1 to 3 , wherein components d) to (m) are formulated for a combination of oral administration, topical administration and/or parenteral administration.
12. Use according to claim 11, wherein component (n) is formulated for oral administration and components d) and (m) are formulated for topical administration.
13. A dosage form comprising, in a single unit, a combination of i) erythromycin, clarithromycin or an analogue or derivative thereof; ii) metronidazole or an analogue or derivative thereof ; and iii) a gastrointestinal hydrogen pump inhibitor.
14. A dosage form according to claim 13 , wherein the gastrointestinal hydrogen pump inhibitor is omeprazole or an analogue or derivative thereof.
15. A dosage form according to claim 13 or claim 14, which is a tablet or capsule.
16. A topical pharmaceutical composition comprising, in a pharmaceutically-acceptable carrier, one or a combination of i) erythromycin, clarithromycin or an analogue or derivative thereof; ii) metronidazole or an analogue or derivative thereof; and iii) a gastrointestinal hydrogen pump inhibitor, such as omeprazole or an analogue or derivative thereof.
17. A parenteral pharmaceutical composition comprising, in a pharmaceutically-acceptable carrier suitable for parenteral administration, one or a combination of i) erythromycin, clarithromycin or an analogue or derivative thereof; ii) metronidazole or an analogue or derivative thereof; and iii) a gastrointestinal hydrogen pump inhibitor, such as omeprazole or an analogue or derivative thereof.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01910045A EP1263445A1 (en) | 2000-03-09 | 2001-03-09 | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin, metronidazole and a gastrointestinal hydrogen pump inhibitor |
| CA002413923A CA2413923A1 (en) | 2000-03-09 | 2001-03-09 | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
| AU37628/01A AU3762801A (en) | 2000-03-09 | 2001-03-09 | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00301951.0 | 2000-03-09 | ||
| EP00301951A EP1133987A1 (en) | 2000-03-09 | 2000-03-09 | Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor |
| US18896100P | 2000-03-10 | 2000-03-10 | |
| US60/188,961 | 2000-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2001066117A1 true WO2001066117A1 (en) | 2001-09-13 |
Family
ID=26073033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2001/001047 WO2001066117A1 (en) | 2000-03-09 | 2001-03-09 | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1263445A1 (en) |
| AU (1) | AU3762801A (en) |
| CA (1) | CA2413923A1 (en) |
| WO (1) | WO2001066117A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003049716A1 (en) * | 2001-12-13 | 2003-06-19 | Ranbaxy Laboratories Limited | Stable topical formulation of clarithromycin |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0472225A2 (en) * | 1985-12-11 | 1992-02-26 | L V M H Recherche | Hydrated lammelar lipidic phases or liposomes containing tretinoid |
| WO1993021920A1 (en) * | 1992-04-24 | 1993-11-11 | Astra Aktiebolag | Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic |
| WO1995018612A1 (en) * | 1994-01-05 | 1995-07-13 | Aktiebolaget Astra | A method for treatment of psoriasis, by omeprazole or related compounds |
| WO1996001622A1 (en) * | 1994-07-08 | 1996-01-25 | Astra Aktiebolag | New oral pharmaceutical formulation containing magnesium salt of omeprazole |
| WO1996024375A1 (en) * | 1995-02-06 | 1996-08-15 | Astra Aktiebolag | New oral pharmaceutical dosage form |
| JPH10158172A (en) * | 1996-11-29 | 1998-06-16 | Takeshi Azuma | Therapeutic agent for hepatic encephalopathy or preventing agent for hepatic encephalopathy |
| WO1999007361A1 (en) * | 1997-08-05 | 1999-02-18 | Millennium Pharmaceuticals, Inc. | Methods for controlling gram negative bacteria in mammals |
| WO1999024036A1 (en) * | 1997-11-07 | 1999-05-20 | Aberdeen University | Skin penetration enhancing components |
-
2001
- 2001-03-09 EP EP01910045A patent/EP1263445A1/en not_active Withdrawn
- 2001-03-09 AU AU37628/01A patent/AU3762801A/en not_active Abandoned
- 2001-03-09 WO PCT/GB2001/001047 patent/WO2001066117A1/en not_active Application Discontinuation
- 2001-03-09 CA CA002413923A patent/CA2413923A1/en not_active Abandoned
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0472225A2 (en) * | 1985-12-11 | 1992-02-26 | L V M H Recherche | Hydrated lammelar lipidic phases or liposomes containing tretinoid |
| JPH09110669A (en) * | 1985-12-11 | 1997-04-28 | Lvmh Rech | Composition for skin disease or for cosmetics |
| WO1993021920A1 (en) * | 1992-04-24 | 1993-11-11 | Astra Aktiebolag | Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic |
| WO1995018612A1 (en) * | 1994-01-05 | 1995-07-13 | Aktiebolaget Astra | A method for treatment of psoriasis, by omeprazole or related compounds |
| WO1996001622A1 (en) * | 1994-07-08 | 1996-01-25 | Astra Aktiebolag | New oral pharmaceutical formulation containing magnesium salt of omeprazole |
| WO1996024375A1 (en) * | 1995-02-06 | 1996-08-15 | Astra Aktiebolag | New oral pharmaceutical dosage form |
| JPH10158172A (en) * | 1996-11-29 | 1998-06-16 | Takeshi Azuma | Therapeutic agent for hepatic encephalopathy or preventing agent for hepatic encephalopathy |
| WO1999007361A1 (en) * | 1997-08-05 | 1999-02-18 | Millennium Pharmaceuticals, Inc. | Methods for controlling gram negative bacteria in mammals |
| WO1999024036A1 (en) * | 1997-11-07 | 1999-05-20 | Aberdeen University | Skin penetration enhancing components |
Non-Patent Citations (5)
| Title |
|---|
| ALDER, J. D. ET AL: "Relevance of the ferret model of Helicobacter-induced gastritis to evaluation of antibacterial therapies", AM. J. GASTROENTEROL. (1996), 91(11), 2347-2354, XP000961369 * |
| DATABASE WPI Week 199834, Derwent World Patents Index; AN 1998-393392, XP002152008 * |
| PATENT ABSTRACTS OF JAPAN vol. 1998, no. 11 30 September 1998 (1998-09-30) * |
| PATENT ABSTRACTS OF JAPAN vol. 1999, no. 06 31 March 1999 (1999-03-31) * |
| XIA, HARRY HUA-XIANG ET AL: "Prospects for improved therapy for Helicobacter pylori infectio", EXPERT OPIN. INVEST. DRUGS (1996), 5(8), 959-976, XP000961342 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003049716A1 (en) * | 2001-12-13 | 2003-06-19 | Ranbaxy Laboratories Limited | Stable topical formulation of clarithromycin |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2413923A1 (en) | 2001-09-13 |
| EP1263445A1 (en) | 2002-12-11 |
| AU3762801A (en) | 2001-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mehrabi et al. | Therapeutic agents in perioperative third molar surgical procedures | |
| US20180264021A1 (en) | Treatment of papulopustular rosacea with ivermectin | |
| ES2389539T3 (en) | Methods and compositions for the treatment of asthma | |
| CA2822320A1 (en) | Composition for the treatment of skin conditions | |
| Schaller et al. | State of the art: systemic rosacea management | |
| US9125927B2 (en) | Compositions comprising avermectin/azelaic acid compounds useful for treating, e.g., rosacea | |
| US8431601B2 (en) | Topical compositions comprising telmesteine for treating dermatological disorders | |
| JP2002525266A5 (en) | ||
| CN113274384B (en) | Application of donkey herbal phenol in preparing medicine for preventing and treating ulcerative colitis and medicine | |
| US20210128548A1 (en) | External preparation comprising pyridonecarboxylic acid derivative | |
| KR101934767B1 (en) | Novel ophthalmic composition and methods of use | |
| US20090163455A1 (en) | Avermectin/hydrocortisone compositions for treating afflictions of the skin, e.g., rosacea | |
| WO2003089007B1 (en) | Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu | |
| KR20190100442A (en) | Composition and method for treating otitis | |
| EP1263445A1 (en) | Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin, metronidazole and a gastrointestinal hydrogen pump inhibitor | |
| EP1133987A1 (en) | Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor | |
| US20140288102A1 (en) | Prevention of recurrences of urethral strictures following conventional therapy | |
| JP2002308764A (en) | Ophthalmic pharmaceutical composition | |
| Vardas et al. | Amiodarone for the restoration of sinus rhythm in patients with atrial fibrillation | |
| EP3664786B1 (en) | Method for treating schnitzler's syndrome | |
| CN115607545B (en) | Edaravone in the treatment of autism spectrum disorders | |
| US6693100B1 (en) | Pharmaceutical compositions for treating psoriasis | |
| JP2018108993A (en) | Enema | |
| Strauss | Complications from Flu is a Taboo | |
| KR20170099911A (en) | Injectable formulations of paracetamol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2001910045 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2001910045 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2413923 Country of ref document: CA |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2001910045 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |